GlassScriptPhysician profile
Jorge L Ajuria
NPI 1194820944
$3,376.72
in general payments reported to CMS, 2019-2025
27 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $112 · 2021: $256 · 2022: $352 · 2023: $746 · 2024: $518 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844 · Education: $62.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.56 |
| Education | $62.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $492.13 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $377.95 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $222.73 | 2019-2024 | Jynarque |
| Alexion Pharmaceuticals, INC. | $220.77 | 2019-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $200.90 | 2019-2025 | Wainua, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $187.84 | 2021-2025 | |
| Horizon Therapeutics Plc | $176.13 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $161.71 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $160.42 | 2021-2025 | Lupkynis |
| Bard Peripheral Vascular, INC. | $138.94 | 2019 | |
| Vifor Pharma, INC. | $135.99 | 2019-2023 | Korsuva, Veltassa |
| Mallinckrodt Enterprises LLC | $134.34 | 2019 | |
| Amgen INC. | $121.45 | 2019-2025 | Tavneos, Krystexxa |
| Merck Sharp & Dohme LLC | $103.53 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.74 | 2023-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.73 | 2022-2025 | Ozempic |
| Kyowa Kirin, INC. | $76.42 | 2024 | Crysvita |
| Fresenius USA Marketing, INC. | $47.20 | 2019-2022 | |
| Ardelyx, INC. | $45.18 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $43.28 | 2019-2025 | |
| Baxter Healthcare | $33.12 | 2019 | |
| Lilly USA, LLC | $24.75 | 2023 | Jardiance |
| Angiodynamics, INC. | $24.19 | 2019 | |
| Calliditas Therapeutics US INC. | $21.98 | 2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $17.58 | 2019 | |
| Glaxosmithkline, LLC. | $15.21 | 2021 | |
| Akebia Therapeutics INC | $13.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ajuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.